Form 8-K LIGAND PHARMACEUTICALS For: May 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Ligand Pharma (LGND) Tops Q1 EPS by 30c
May 4, 2016 8:16 AM EDTLigand Pharma (NASDAQ: LGND) reported Q1 EPS of $0.97, $0.30 better than the analyst estimate of $0.67. Revenue for the quarter came in at $29.6 million versus the consensus estimate of $26.45 million.
GUIDANCE:
Ligand Pharma sees FY2016 EPS of $3.41-$3.46, versus the consensus of... More



